Cell and Gene Therapy Updates

February 3rd Week, 2025

📝 BMS’ Breyanzi (liso-cel; an autologous, anti-CD19 CAR-T) received NICE recommendation as an option for treating Relapsed or Refractory Large B-cell Lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (Ref 1) 

❓ What new evidence led NICE to overturn its initial rejection of Breyanzi in Oct 2024? 

📝 Anixa Biosciences received the approval to amend Ovarian Cancer Phase 1/NCT05316129 trial, allowing a second dose of FSHR CER-T (an autologous, Follicle Stimulating Hormone-specific chimeric endocrine receptor-T) and including more Ovarian Cancer histologies (sex cord-stromal tumors and Sertoli Leydig cell tumors) (Ref 2) 

❓ What is the significance of the protocol amendment for this trial?

To know answers to these questions and for additional insights, write to us at support@oncofocus.com

🌐 References:

1) https://www.nice.org.uk/guidance/ta1048/history

2) https://ir.anixa.com/press-releases/detail/1066/anixa-biosciences-announces-approval-of-protocol-amendment